Related Posts
HSCA Comments to the Senate Committee on Health, Education, Labor, and Pensions on the PREVENT Pandemics Act
April 1, 2022
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Support Letter to the House Committee on Energy & Commerce on House Passage of FDA User Fee Reauthorizations
June 30, 2022
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Response to Congressional RFI on the Pandemic and All-Hazards Preparedness Act (PAHPA)
March 16, 2023
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Response to Senate Committee on Health, Education, Labor, and Pensions (HELP) RFI on the Pandemic and All-Hazards Preparedness Act (PAHPA)
April 5, 2023
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Support Letter to the House Committee on Energy & Commerce on House Passage of FDA User Fee Reauthorizations
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), we applaud the bipartisan leadership of Chairman Pallone, Chairwoman Eshoo, Ranking Member Rodgers, and Ranking Member Guthrie of the House Committee on Energy & Commerce on the Food and Drug Amendments Act of 2022, which the House of Representatives recently passed with overwhelming support by a vote of 392-28. Timely access to safe and effective drugs, devices, products, and biologics for all Americans is of critical importance to GPOs, which serve as the sourcing partners to virtually all hospitals, clinics, ambulatory surgery centers, and long-term care facilities.
Click here to read the full letter.